Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.43 |
| ▸ | DRD2 | P14416 | 8/20 | 0.43 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.40 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.40 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.40 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9739825 | 0.79 | TAAR1 (0.36) | TSHRNPSR1KDM1A | |
| SCHEMBL9738560 | 0.77 | ALDH1A1 (0.38) | TSHRCASP1KDM1A | |
| SCHEMBL4378996 | 0.69 | DRD2 (0.50) | DRD3DRD2ABCC9ABCC8KCNJ11 | |
| SCHEMBL29813085 | 0.69 | DRD2 (0.50) | DRD3DRD2ABCC9ABCC8KCNJ11 | |
| SCHEMBL18975675 | 0.69 | DRD2 (0.46) | DRD3DRD2ABCC9ABCC8KCNJ11 | |
| SCHEMBL6540021 | 0.69 | DRD2 (0.50) | DRD3DRD2ABCC9ABCC8KCNJ11 | |
| SCHEMBL16412900 | 0.69 | DRD2 (0.50) | DRD3DRD2ABCC9ABCC8KCNJ11 | |
| SCHEMBL4875328 | 0.68 | DRD2 (0.67) | DRD3DRD2ABCC9ABCC8KCNJ11 | |
| SCHEMBL10703931 | 0.68 | MAPT (0.42) | CASP1NPSR1MAOAMAOB | |
| SCHEMBL17696870 | 0.68 | DRD2 (0.53) | DRD3DRD2ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916805-B2 | Quinoxalinones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-07-12 | — | — | US | disclosed |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | disclosed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | disclosed |
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | DUDLEY DANETTE ANDREA (US) | 2002-07-04 | — | — | US | disclosed |
| US-6410536-B1 | ANTICOAGULANTS | WARNER-LAMBERT COMPANY | 2002-06-25 | — | — | US | disclosed |
| EP-1068190-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050254-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | HABP2, SERPINB1, PRSS1 | DRD3 4406/4885DRD2 4574/4885ABCC9 703/4885 |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | HABP2, SPINT2, SERPINB1 | DRD3 4578/4885DRD2 4676/4885ABCC9 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.